Labopharm initiated the formal dispute resolution process in October 2007 after receiving an approvable letter from the FDA for its once-daily formulation of tramadol in May.
The FDA has said that Labopharm did not demonstrate the drug’s effectiveness since the methods used to analyze clinical trial data did not address missing data from patients who had dropped out of the study.